Jazz Pharmaceuticals announced positive results from its HERIZON-GEA-01 trial, showing that Ziihera, combined with chemotherapy, significantly improved overall survival in adults with HER2-positive gastroesophageal adenocarcinoma (GEA) compared to the previous standard treatment. This reinforces Ziihera as the new HER2-targeted backbone therapy for first-line GEA, following its recent FDA approval. The company plans to submit these data for presentation at a major medical meeting and to global health authorities, aiming to establish Ziihera as the new standard of care.
The InLight Foundation held a major forum at Stanford University following the 2026 Nobel Prize in Physiology or Medicine awarded for optogenetics. Experts from top universities and tech firms discussed new frontiers in consciousness regulation, high...
Lisk has urged all liquidity providers in the Uniswap ETH/LSK pool to temporarily withdraw their positions, which will reduce the available liquidity for this trading pair. The request is temporary, but no timeline was given for when providers should...
The XRP Ledger Foundation has updated its recommended validator list by adding Flare and removing Anodos Finance, which requested removal as it plans to retire its validator by the end of October. This change affects the Foundation's guidance for ser...
Aave froze reserves on multiple V3 and V4 networks after a wallet linked to the Binance hot-wallet exploit borrowed nearly $44.6 million in wrapped Ether (WETH). The wallet had initially supplied $60 million in Tether (USDT) before borrowing. Users w...
Strategy Executive Chairman Michael Saylor revealed the company could generate up to $30 billion in digital credit from its existing balance sheet to finance additional Bitcoin purchases. CEO Phong Le emphasized that issuing digital credit, such as p...
